Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
08:00am, Wednesday, 08'th Mar 2023
TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Confe
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
09:02am, Wednesday, 01'st Mar 2023
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.
Pacira BioSciences, Inc. (PCRX) Q4 2022 Earnings Call Transcript
12:50pm, Tuesday, 28'th Feb 2023
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
08:00am, Tuesday, 21'st Feb 2023
TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before t
After Plunging -17.19% in 4 Weeks, Here's Why the Trend Might Reverse for Pacira (PCRX)
11:17am, Thursday, 05'th Jan 2023
The heavy selling pressure might have exhausted for Pacira (PCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
3 Reasons Growth Investors Will Love Pacira (PCRX)
02:18pm, Wednesday, 04'th Jan 2023
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira (PCRX) Loses -17.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Wednesday, 04'th Jan 2023
Pacira (PCRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 04'th Jan 2023
TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM E
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
11:36am, Wednesday, 28'th Dec 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
All You Need to Know About Pacira (PCRX) Rating Upgrade to Buy
01:33pm, Friday, 09'th Dec 2022
Pacira (PCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?
03:11pm, Friday, 18'th Nov 2022
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
12:03pm, Friday, 04'th Nov 2022
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Pacira BioSciences, Inc. (PCRX) Q3 2022 Earnings Call Transcript
02:36pm, Thursday, 03'rd Nov 2022
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive
Assessing Pacira BioSciences' Growth Prospects
01:00pm, Thursday, 20'th Oct 2022
Exparel continues to face headwinds in the near term but should continue to grow in the following years. Zilretta has not done well since last year's acquisition, but there are objective issues that P
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
08:00am, Thursday, 20'th Oct 2022
TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu
